A Different bispecific, humanized IgG1 antibody that is underneath investigation is zenocutuzumab (MCLA-128), which functions by using two unbiased mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells by way of ADCC. MCLA-128 functions through a ‘dock and block’ system whereby a person arm in the antibody https://www.directivepublications.org/journal-of-clinical-breast-cancer/